iBio Appoints Robert M. Lutz as Chief Monetary & Business Officer

BRYAN, Texas, Feb. 16, 2021 (Globe NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics deal production corporation, right now introduced the appointment of Robert M. Lutz as its Chief Monetary & Business Officer (“CFBO”), productive March 4, 2021.

“I am delighted to welcome Rob to iBio in which we assume he will make an instant effects on our business enterprise during this transformative time,” mentioned Tom Isett, Chairman & CEO of iBio. “His deep encounter across corporate finance and enterprise advancement functions, breadth of community business experience, and shown experience in setting up solution portfolios is a remarkable in shape for iBio as we request to execute on our new enterprise model.”

Mr. Lutz provides a lot more than 25 many years of expertise to the Organization, signing up for most lately from Strongbridge Biopharma plc (“Strongbridge”), a Nasdaq-stated, industrial-stage biopharmaceutical firm concentrated on unusual diseases. He served as CFO given that August 2019, and prior to that, as Chief Organization Officer considering the fact that October 2014. All through his tenure, he led the research, analysis, contracting, and funding of a number of belongings which proved to be significant expansion motorists for Strongbridge.

Prior to joining Strongbridge, Mr. Lutz invested extra than a decade at Shire Pharmaceuticals (“Shire”) in leadership positions with world-wide tasks, which includes identifying options for acquisition, licensing, partnership and development for Shire’s largest organization device (Neuroscience) and the monetary management of about $5 billion in profits for its Specialty Prescription drugs division. Prior to becoming a member of Shire, Mr. Lutz served in a variety of financial, strategic and govt positions immediately after acquiring began his profession at Goldman Sachs & Corporation. He holds an MBA from the Kellogg College of Administration and a BA in Economics and Computer Science from Amherst College.

“It is an fascinating time to be signing up for iBio,” Mr. Lutz commented. “There is a exclusive opportunity to leverage the strengths of the Company’s superior-speed, plant-based biopharmaceutical generation capabilities throughout various product or service categories and therapeutic parts. I seem ahead to doing work with the team to broaden the solution pipeline, speed up growth, and boost benefit for our shareholders.”

As CFBO, Mr. Lutz will lead iBio’s finance corporation and be responsible for constructing solid licensing capabilities and the financial arranging & analysis function, as effectively as supporting iBio’s interactions with the investment community.

About iBio, Inc.

iBio is a worldwide chief in plant-based biologics producing. Its FastPharming® Technique brings together vertical farming, automated hydroponics, and novel glycosylation systems to promptly supply higher-high quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is establishing proprietary items on the FastPharming Platform, which include things like biopharmaceuticals for the treatment method of fibrotic and infectious diseases, among many others. The Company’s subsidiary, iBio CDMO LLC, gives FastPharming Deal Development and Production Solutions, which include Glycaneering™ Enhancement Products and services for highly developed recombinant protein style. For much more data, go to www.ibioinc.com.

Forward-Wanting STATEMENTS

Specific statements in this push release constitute “forward-on the lookout statements” within just the this means of the federal securities laws. Phrases these types of as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or very similar expressions, or statements relating to intent, perception, or latest expectations, are ahead-searching statements. These forward-wanting statements are centered upon present-day estimates and assumptions and involve statements concerning the envisioned contribution of Mr. Lutz, executing the Company’s new business design, and growing the Company’s merchandise pipeline, accelerating development, and maximizing price for our shareholders. Though the Organization thinks these ahead-hunting statements are acceptable, undue reliance should really not be put on any these types of ahead-wanting statements, which are based on details obtainable to us on the date of this release. These ahead-seeking statements are subject to several hazards and uncertainties, several of which are difficult to forecast that could lead to true results to differ materially from latest anticipations and assumptions from all those set forth or implied by any ahead-searching statements. Significant elements that could bring about real final results to differ materially from recent anticipations involve, amongst other people, the contribution of Mr. Lutz, the Company’s potential to expand its products pipeline, the Company’s capability to attain regulatory approvals for commercialization of its merchandise candidates, which include its infectious illness vaccines, or to comply with ongoing regulatory necessities, regulatory restrictions relating to its skill to encourage or commercialize its products candidates for certain indications, acceptance of its product candidates in the market and the profitable improvement, marketing and advertising or sale of merchandise, its means to sustain its license agreements, the continued routine maintenance and growth of its patent estate, its capacity to create and sustain collaborations, its potential to get or retain the funds or grants vital to fund its analysis and improvement actions, level of competition, its skill to retain its essential staff members or retain its NYSE American listing, and the other aspects discussed in the Company’s Annual Report on Variety 10-K for the yr finished June 30, 2020 and the Company’s subsequent filings with the SEC, together with subsequent periodic reports on Variety 10-Q and Kind 8-K. The information in this launch is furnished only as of the date of this release, and we undertake no obligation to update any forward-hunting statements contained in this launch on account of new facts, potential activities, or if not, apart from as required by regulation.

Speak to:

Stephen Kilmer
iBio, Inc.
Trader Relations
(646) 274-3580
[email protected]